The Role of Oxidative Damage to Nucleic Acids in the Pathogenesis of Neurological Disease

  • V. Prakash Reddy
  • Ayse Beyaz
  • George Perry
  • Marcus S. Cooke
  • Lawrence M. Sayre
  • Mark A. Smith
Part of the Molecular Biology Intelligence Unit book series (MBIU)


Oxidative stress involving reactive oxygen species (ROS) and reactive nitrogen species (RNS) is integral to the process of aging and age-related diseases such as Alzheimer disease (AD), Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). Oxidative stress-induced modification of nucleic acids impacts on the function of the cell, which can have an important role in the cause of AD. ROS induces hydroxylation of nucleic acid bases (e.g., formation of 8-hydroxy-2′ deoxyguanosine (8-OHdG) from deoxyguanosine), and RNS induces their hydroxylative deamination (e.g. cytosine to uracil conversion). 8-OHdG is commonly used as a marker of DNA damage in AD and other age-related diseases, and is approximately 10-fold higher than other oxidized bases. It is present in significant amounts in the mitochondrail and nuclear DNA of AD brains, as compared to control cases. Mitochondrial DNA is relatively more prone to damage as it is exposed to increased concentrations of ROS. In addition to transversion mutations of nucleic acid bases, oxidative stress-induced DNA damage results in delterious DNA-DNA and DNA-protein crosslinking. DNA-DNA crosslinks may also be initiated by RNS-induced deamination of nucleic acid bases. ROS can also modify amyloid-β, through the oxidation of its constituent methionines to the corresponding radical cations, which initiate free radical chain reactions leading to its aggregation. Nucleic acids are also damaged through the mediation of advanced lipid peroxidation products, such as trans-4-hydroxynonenal (HNE) and 4-oxo-2-nonenal (ONE), which result in the formation of the corresponding “propano-” and “etheno-” adducts. The substantial DNA damage in AD reflects impaired mitochondrial function in the cases of AD, which results in increased ROS/RNS and decreased ATP formation, the latter impacting on the DNA repair.


Amyotrophic Lateral Sclerosis Alzheimer Disease Nucleotide Excision Repair Reactive Nitrogen Species Lipid Peroxidation Product 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Moreira PI, Honda K, Liu Q et al. Alzheimer’s disease and oxidative stress: The old problem remains unsolved. Curr Med Chem—Cent Nerv Syst Agents 2005; 5:51–62.Google Scholar
  2. 2.
    Loft S, Poulsen HE. Cancer risk and oxidative DNA damage in man. J Mol Med 1996; 74:297–312.PubMedCrossRefGoogle Scholar
  3. 3.
    Harman D. The free radical theory of aging. Antioxid Redox Signal 2003; 5:557–561.PubMedCrossRefGoogle Scholar
  4. 4.
    Smith MA, Nunomura A, Zhu X et al. Metabolic, metallic, and mitotic sources of oxidative stress in Alzheimer disease. Antioxid Redox Signal 2000; 2:413–420.PubMedCrossRefGoogle Scholar
  5. 5.
    Smith MA, Rottkamp CA, Nunomura A et al. Oxidative stress in Alzheimer’s disease. Biochim Biophys Acta 2000; 1502:139–144.PubMedGoogle Scholar
  6. 6.
    Perry G, Sayre LM, Atwood CS et al. The role of iron and copper in the actiology of neurodegenerative disorders: Therapeutic implications. CNS Drugs 2002; 16:339–352.PubMedCrossRefGoogle Scholar
  7. 7.
    Sayre LM, Smith MA, Perry G. Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr Med Chem 2001; 8:721–738.PubMedGoogle Scholar
  8. 8.
    Evans MD, Cooke MS. Factors contributing to the outcome of oxidative damage to nucleic acids. Bioessays 2004; 26:533–542.PubMedCrossRefGoogle Scholar
  9. 9.
    Evans MD, Dizdaroglu M, Cooke MS. Oxidative DNA damage and disease: Induction, repair and significance. Mutat Res 2004; 567:1–61.PubMedCrossRefGoogle Scholar
  10. 10.
    Nunomura A, Perry G, Aliev G et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001; 60:759–767.PubMedGoogle Scholar
  11. 11.
    Nunomura A, Perry G, Pappolla MA et al. Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. J Neuropathol Exp Neurol 2000; 59:1011–1017.PubMedGoogle Scholar
  12. 12.
    Hirai K, Aliev G, Nunomura A et al. Mitochondrial abnormalities in Alzheimer’s disease. J Neurosci 2001; 21:3017–3023.PubMedGoogle Scholar
  13. 13.
    Sayre LM, Perry G, Harris PL et al. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer’s disease: A central role for bound transition metals. J Neurochem 2000; 74:270–279.PubMedCrossRefGoogle Scholar
  14. 14.
    Smith MA, Harris PL, Sayre LM et al. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 1997; 94:9866–9868.PubMedCrossRefGoogle Scholar
  15. 15.
    Price DL, Rhett PM, Thorpe SR et al. Chelating activity of advanced glycation end-product inhibitors. J Biol Chem 2001; 276:48967–48972.PubMedCrossRefGoogle Scholar
  16. 16.
    Gotz ME, Wacker M, Luckhaus C et al. Unaltered brain levels of 1,N2-propanodeoxyguanosine adducts of trans-4-hydroxy-2-nonenal in Alzheimer’s disease. Neurosci Lett 2002; 324:49–52.PubMedCrossRefGoogle Scholar
  17. 17.
    Reddy VP, Garrett MR, Perry G et al. Carnosine: A versatile antioxidant and antiglycating agent. Sci Aging Knowledge Environ 2005; (May 4), 2005(18), pe12.CrossRefGoogle Scholar
  18. 18.
    Richeson CE, Mulder P, Bowry VW et al. The complex chemistry of peroxynitrite decomposition: New insights. Journal of the American Chemistry Society 1998; 120:7211–7219.CrossRefGoogle Scholar
  19. 19.
    Schoneich C. Methionine oxidation by reactive oxygen species: Reaction mechanisms and relevance to Alzheimer’s disease. Biochim Biophys Acta 2005; 1703:111–119.PubMedGoogle Scholar
  20. 20.
    Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. 3rd ed. New York: Oxford University Press, 1999.Google Scholar
  21. 21.
    Simic G, Lucassen PJ, Krsnik Z et al. nNOS expression in reactive astrocytes correlates with increased cell death related DNA damage in the hippocampus and entorhinal cortex in Alzheimer’s disease. Exp Neurol 2000; 165:12–26.PubMedCrossRefGoogle Scholar
  22. 22.
    Smith MA, Richey Harris PL, Sayre LM et al. Widespread peroxynitrite-mediated damage in Alzheimer’s disease. J Neurosci 1997; 17:2653–2657.PubMedGoogle Scholar
  23. 23.
    Barker S, Weinfeld M, Murray D. DNA-protein crosslinks: Their induction, repair, and biological consequences. Mutat Res 2005; 589:111–135.PubMedCrossRefGoogle Scholar
  24. 24.
    Nakano T, Terato H, Asagoshi K et al. DNA-protein cross-link formation mediated by oxanine. A novel genotoxic mechanism of nitric oxide-induced DNA damage. J Biol Chem 2003; 278:25264–25272.PubMedCrossRefGoogle Scholar
  25. 25.
    Caulfield JL, Wishnok JS, Tannenbaum SR. Nitric oxide-induced interstrand cross-links in DNA. Chem Res Toxicol 2003; 16:571–574.PubMedCrossRefGoogle Scholar
  26. 26.
    Huang X, Moir RD, Tanzi RE et al. Redox-active metals, oxidative stress, and Alzheimer’s disease pathology. Ann NY Acad Sci 2004; 1012:153–163.PubMedCrossRefGoogle Scholar
  27. 27.
    Bozner P, Grishko V, LeDoux SP et al. The amyloid β protein induces oxidative damage of mitochondrial DNA. J Neuropathol Exp Neurol 1997; 56:1356–1362.PubMedCrossRefGoogle Scholar
  28. 28.
    Curtain CC, Ali F, Volitakis I et al. Alzheimer’s disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J Biol Chem 2001; 276:20466–20473.PubMedCrossRefGoogle Scholar
  29. 29.
    Rottkamp CA, Raina AK, Zhu X et al. Redox-active iron mediates amyloid-beta toxicity, Free Radic Biol Med 2001; 30:447–450.PubMedCrossRefGoogle Scholar
  30. 30.
    Smith MA, Joseph JA, Perry G. Arson. Tracking the culprit in Alzheimer’s disease. Ann NY Acad Sci 2000; 924:35–38.PubMedGoogle Scholar
  31. 31.
    Castellani RJ, Honda K, Zhu X et al. Contribution of redox-active iron and copper to oxidative damage in Alzheimer disease. Ageing Res Rev 2004; 3:319–326.PubMedCrossRefGoogle Scholar
  32. 32.
    Shibutani S, Takeshita M, Grollman AP. Insertion of specific bases during DNA synthesis past the oxidation-damaged base 8-oxodG. Nature 1991; 349:431–434.PubMedCrossRefGoogle Scholar
  33. 33.
    Cheng KC, Cahill DC, Kasai H et al. 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G—T and A—C substitutions. J Biol Chem 1992; 267:166–172.PubMedGoogle Scholar
  34. 34.
    Wallace DC. Mitochondrial genetics: A paradigm for aging and degenerative diseases? Science 1992; 256:628–632.PubMedCrossRefGoogle Scholar
  35. 35.
    Douki T, Ravanat JL, Frelon S et al. HPLC-MS/MS measurement of oxidative base damage to isolated and cellular DNA. Critical Reviews of Oxidative Stress and Aging 2003; 1:190–202.Google Scholar
  36. 36.
    Cooke MS, Lunec J. Immunochemical detection of oxidative DNA damage. In: Cutler RG Rodriguez H, eds. Oxidative Stress and Aging: Advances in Basic Science, Diagnostics and Intervention. New York: World Scientific Publishing, 2003:275–293.Google Scholar
  37. 37.
    Edfeldt NB, Harwood EA, Sigurdsson ST et al. Sequence context effect on the structure of nitrous acid induced DNA interstrand cross-links. Nucleic Acids Res 2004; 32:2795–2801.PubMedCrossRefGoogle Scholar
  38. 38.
    Arlt S, Muller-Thomsen T, Beisiegel U. Use of vitamin C and E in the treatment of Alzheimer’s disease. Drug Dev Res 2002; 56:452–457.CrossRefGoogle Scholar
  39. 39.
    Marklund SL, Adolfsson R, Gottfries CG et al. Superoxide dismutase isoenzymes in normal brains and in brains from patients with dementia of Alzheimer type. J Neurol Sci 1985; 67:319–325.PubMedCrossRefGoogle Scholar
  40. 40.
    Castellani RJ, Harris PL, Sayre LM et al. Active glycation in neurofibrillary pathology of Alzheimer disease: N(epsilon)-(carboxymethyl) lysine and hexitol-lysine. Free Radic Biol Med 2001; 31:175–180.PubMedCrossRefGoogle Scholar
  41. 41.
    Reddy VP, Obrenovich ME, Atwood CS et al. Involvement of Maillard reactions in Alzheimer disease. Neurotox Res 2002; 4:191–209.PubMedCrossRefGoogle Scholar
  42. 42.
    Smith MA, Sayre LM, Monnier VM et al. Radical AGEing in Alzheimer’s disease. Trends Neurosci 1995; 18:172–176.PubMedCrossRefGoogle Scholar
  43. 43.
    Smith MA, Taneda S, Richey PL et al. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci USA 1994; 91:5710–5714.PubMedCrossRefGoogle Scholar
  44. 44.
    Smith ML, Chen IT, Zhan Q et al. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 1994; 266:1376–1380.PubMedCrossRefGoogle Scholar
  45. 45.
    Vitek MP, Bhattacharya K, Glendening JM et al. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci USA 1994; 91:4766–4770.PubMedCrossRefGoogle Scholar
  46. 46.
    Yan SD, Chen X, Schmidt AM et al. Glycated tau protein in Alzheimer disease: A mechanism for induction of oxidant stress. Proc Natl Acad Sci USA 1994; 91:7787–7791.PubMedCrossRefGoogle Scholar
  47. 47.
    Sayre LM, Zelasko DA, Harris PL et al. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer’s disease. J Neurochem 1997; 68:2092–2097.PubMedGoogle Scholar
  48. 48.
    Takeda A, Smith MA, Avila J et al. In Alzheimer’s disease, heme oxygenase is coincident with Alz50, an epitope of tau induced by 4-hydroxy-2-nonenal modification. J Neurochem 2000; 75:1234–1241.PubMedCrossRefGoogle Scholar
  49. 49.
    Wataya T, Nunomura A, Smith MA et al. High molecular weight neurofilament proteins are physiological substrates of adduction by the lipid peroxidation product hydroxynonenal. J Biol Chem 2002; 277:4644–4648.PubMedCrossRefGoogle Scholar
  50. 50.
    Richter T, Munch G, Luth HJ et al. Immunochemical crossreactivity of antibodies specific for “advanced glycation endproducts” with “advanced lipoxidation endproducts”. Neurobiol Aging 2005; 26:465–474.PubMedCrossRefGoogle Scholar
  51. 51.
    Munch G, Schinzel R, Loske C et al. Alzheimer’s disease—synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm 1998; 105:439–461.PubMedCrossRefGoogle Scholar
  52. 52.
    Yamagishi S, Nakamura K, Inoue H et al. Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation, end products (AGEs) may be a promising biomarker for early detection of Alzheimer’s disease. Med Hypotheses 2005; 64:1205–1207.PubMedCrossRefGoogle Scholar
  53. 53.
    Ahmed N, Ahmed U, Thornalley PJ et al. Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer’s disease and link to cognitive impairment. J Neurochem 2005; 92:255–263.PubMedCrossRefGoogle Scholar
  54. 54.
    Kaufmann E, Boehm BO, Sussmuth SD et al. The advanced glycation end-product Nε-(carboxymethyl)lysine level is elevated in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Neurosci Lett 2004; 371:226–229.PubMedCrossRefGoogle Scholar
  55. 55.
    Gong CX, Liu F, Grundke-Iqbal I et al. Post-translational modifications of tau protein in Alzheimer’s disease. J Neural Transm 2005; 112:813–838.PubMedCrossRefGoogle Scholar
  56. 56.
    Hobart LJ, Seibel I, Yeargans GS et al. Anti-crosslinking properties of carnosine: Significance of histidine. Life Sci 2004; 75:1379–1389PubMedCrossRefGoogle Scholar
  57. 57.
    Chung FL, Nath RG, Nagao M et al. Endogenous formation and significance of 1,N2-propanodeoxy-guanosine adducts. Mutat Res 1999; 424:71–81.PubMedGoogle Scholar
  58. 58.
    Chung FL, Pan J, Choudhury S et al. Formation of trans-4-hydroxy-2-nonenal-and other enal-derived cyclic DNA adducts from omega-3 and omega-6 polyunsaturated fatty acids and their roles in DNA repair and human p53 gene mutation. Mutat Res 2003; 531:25–36.PubMedGoogle Scholar
  59. 59.
    Pan J, Chung FL. Formation of cyclic deoxyguanosine adducts from omega-3 and omega-6 polyunsaturated fatty acids under oxidative conditions. Chem Res Toxicol 2002; 15:367–372.PubMedCrossRefGoogle Scholar
  60. 60.
    Burcham PC. Genotoxic lipid peroxidation products: Their DNA damaging properties and role in formation of endogenous DNA adducts. Mutagenesis 1998; 13:287–305.PubMedCrossRefGoogle Scholar
  61. 61.
    Fernandes PH, Wang H, Rizzo CJ et al. Site-specific mutagenicity of stereochemically defined 1,N2-deoxyguanosine adducts of trans-4-hydroxynonenal in mammalian cells. Environ Mol Mutagen 2003; 42:68–74.PubMedCrossRefGoogle Scholar
  62. 62.
    Hussain SP, Raja K, Amstad PA et al. Increased p53 mutation load in nontumorous human liver of wilson disease and hemochromatosis: Oxyradical overload diseases. Proc Natl Acad Sci USA 2000; 97:12770–12775.PubMedCrossRefGoogle Scholar
  63. 63.
    Yang IY, Chan G, Miller H et al. Mutagenesis by acrolein-derived propanodeoxyguanosine adducts in human cells. Biochemistry 2002; 41:13826–13832.PubMedCrossRefGoogle Scholar
  64. 64.
    Lee SH, Blair IA. Characterization of 4-oxo-2-nonenal as a novel product of lipid peroxidation. Chem Res Toxicol 2000; 13:698–702.PubMedCrossRefGoogle Scholar
  65. 65.
    Spiteller P, Kern W, Reiner J et al. Aldehydic lipid peroxidation products derived from linoleic acid. Biochim Biophys Acta 2001; 1531:188–208.PubMedGoogle Scholar
  66. 66.
    Blair IA. Lipid hydroperoxide-mediated DNA damage. Exp. Gerontol 2001; 36:1473–1481.PubMedCrossRefGoogle Scholar
  67. 67.
    Kawai Y, Uchida K, Osawa T. 2′-deoxycytidine in free nucleosides and double-stranded DNA as the major target of lipid peroxidation products. Free Radic Biol Med 2004; 36:529–541.PubMedCrossRefGoogle Scholar
  68. 68.
    Pollack M, Oe T, Lee SH et al. Characterization of 2′-deoxycytidine adducts derived from 4-oxo-2-nonenal, a novel lipid peroxidation product. Chem Res Toxicol 2003; 16:893–900.PubMedCrossRefGoogle Scholar
  69. 69.
    Rindgen D, Lee SH, Nakajima M et al. Formation of a substituted 1,N(6)-etheno-2′-deoxyadenosine adduct by lipid hydroperoxide-mediated generation of 4-oxo-2-nonenal. Chem Res Toxicol 2000; 13:846–852.PubMedCrossRefGoogle Scholar
  70. 70.
    Rindgen D, Nakajima M, Wehrli S et al. Covalent modifications to 2′-deoxyguanosine by 4-oxo-2-nonenal, a novel product of lipid peroxidation. Chem Res Toxicol 1999; 12:1195–1204.PubMedCrossRefGoogle Scholar
  71. 71.
    Chen HJ, Chung FL. Formation of etheno adducts in reactions of enals via autoxidation. Chem Res Toxicol 1994; 7:857–860.PubMedCrossRefGoogle Scholar
  72. 72.
    Douki T, Odin F, Caillat S et al. Predominance of the 1,N2-propano 2′-deoxyguanosine adduct among 4-hydroxy-2-nonenal-induced DNA lesions. Free Radic Biol Med 2004; 37:62–70.PubMedCrossRefGoogle Scholar
  73. 73.
    Lin D, Lee HG, Liu Q et al. 4-Oxo-2-nonenal is both more neurotoxic and protein reactive than 4-hydroxy-2-nonenal. Chem Res Toxicol 2005; 18: in press.Google Scholar
  74. 74.
    Sowell J, Frei B, Stevens JF. Vitamin C conjugates of genotoxic lipid peroxidation products: Structural characterization and detection in human plasma. Proc Natl Acad Sci USA 2004; 101:17964–17969.PubMedCrossRefGoogle Scholar
  75. 75.
    Zhang WH, Liu J, Xu G et al. Model studies on protein side chain modification by 4-oxo-2-nonenal. Chem Res Toxicol 2003; 16:512–523.PubMedCrossRefGoogle Scholar
  76. 76.
    Feng Z, Hu W, Tang MS. Trans-4-hydroxy-2-nonenal inhibits nucleotide excision repair in human cells: A possible mechanism for lipid peroxidation-induced carcinogenesis. Proc Natl Acad Sci USA 2004; 101:8598–8602.PubMedCrossRefGoogle Scholar
  77. 77.
    West JD, Ji C, Duncan ST et al. Induction of apoptosis in colorectal carcinoma cells treated with 4-hydroxy-2-nonenal and structurally related aldehydic products of lipid peroxidation. Chem Res Toxicol 2004; 17:453–462.PubMedCrossRefGoogle Scholar
  78. 78.
    Aldini G, Carini M, Beretta G et al. Carnosine is a quencher of 4-hydroxy-nonenal: Through what mechanism of reaction. Biochem Biophys Res Commun 2002; 298:699–706.PubMedCrossRefGoogle Scholar
  79. 79.
    Aldini G, Granata P, Carini M. Detoxification of cytotoxic alpha,beta-unsaturated aldehydes by carnosine: Characterization of conjugated adducts by electrospray ionization tandem mass spectrometry and detection by liquid chromatography/mass spectrometry in rat skeletal muscle. J Mass Spectrom 2002; 37:1219–1228.PubMedCrossRefGoogle Scholar
  80. 80.
    Xie C, Lovell MA, Markesbery WR. Glutathione transferase protects neuronal cultures against four hydroxynonenal toxicity. Free Radic Biol Med 1998; 25:979–988.PubMedCrossRefGoogle Scholar
  81. 81.
    Chung FL, Komninou D, Zhang L et al. Glutathione depletion enhances the formation of endogenous cyclic DNA adducts derived from t-4-hydroxy-2-nonenal in rat liver. Chem Res Toxicol 2005; 18:24–27.PubMedCrossRefGoogle Scholar
  82. 82.
    Breen AP, Murphy JA. Reactions of oxyl radicals with DNA. Free Radic Biol Med 1995; 18:1033–1077.PubMedCrossRefGoogle Scholar
  83. 83.
    Aruoma OI, Halliwell B, Dizdaroglu M. Iron ion-dependent modification of bases in DNA by the superoxide radical-generating system hypoxanthine/xanthine oxidase. J Biol Chem 1989; 264:13024–13028.PubMedGoogle Scholar
  84. 84.
    Gajewski E, Rao G, Nackerdien Z et al. Modification of DNA bases in mammalian chromatin by radiation-generated free radicals. Biochemistry 1990; 29:7876–7882.PubMedCrossRefGoogle Scholar
  85. 85.
    Lyras L, Cairns NJ, Jenner A et al. An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer’s disease. J Neurochem 1997; 68:2061–2069.PubMedCrossRefGoogle Scholar
  86. 86.
    Gabbita SP, Lovell MA, Markesbery WR. Increased nuclear DNA oxidation in the brain in Alzheimer’s disease. J Neurochem 1998; 71:2034–2040.PubMedGoogle Scholar
  87. 87.
    Lovell MA, Gabbita SP, Markesbery WR. Increased DNA oxidation and decreased levels of repair products in Alzheimer’s disease ventricular CSF. J Neurochem 1999; 72:771–776.PubMedCrossRefGoogle Scholar
  88. 88.
    Kadioglu E, Sardas S, Aslan S et al. Detection of oxidative DNA damage in lymphocytes of patients with Alzheimer’s disease. Biomarkers; 2004; 9:203–209.PubMedCrossRefGoogle Scholar
  89. 89.
    Lovell MA, Xie C, Markesbery WR. Decreased base excision repair and increased helicase activity in Alzheimer’s disease brain. Brain Res 2000; 855:116–123.PubMedCrossRefGoogle Scholar
  90. 90.
    Nunomura A, Perry G, Pappolla MA et al. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer’s disease. J Neurosci 1999; 19:1959–1964.PubMedGoogle Scholar
  91. 91.
    Hoffmann S, Spitkovsky D, Radicella JP et al. Reactive oxygen species derived from the mitochondrial respiratory chain are not responsible for the basal levels of oxidative base modifications observed in nuclear DNA of Mammalian cells. Free Radic Biol Med 2004; 36:765–773.PubMedCrossRefGoogle Scholar
  92. 92.
    Doerge DR, Churchwell MI, Fang JL et al. Quantification of etheno-DNA adducts using liquid chromatography, on-line sample processing, and electrospray tandem mass spectrometry. Chem Res Toxicol 2000; 13:1259–1264.PubMedCrossRefGoogle Scholar
  93. 93.
    Mecocci P, MacGarvey U, Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer’s disease. Ann Neurol 1994; 36:747–751.PubMedCrossRefGoogle Scholar
  94. 94.
    Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci USA 1993; 90:7915–7922.PubMedCrossRefGoogle Scholar
  95. 95.
    Wang J, Xiong S, Xie C et al. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer’s disease. J Neurochem 2005; 93:953–962.PubMedCrossRefGoogle Scholar
  96. 96.
    Crawford DR, Suzuki T, Sesay J et al. Analysis of gene expression following oxidative stress. Methods Mol Biol 2002; 196:155–162.PubMedGoogle Scholar
  97. 97.
    Chen JJ, Yu BP. Alterations in mitochondrial membrane fluidity by lipid peroxidation products. Free Radic Biol Med 1994; 17:411–418.PubMedCrossRefGoogle Scholar
  98. 98.
    Mecocci P, MacGarvey U, Kaufman AE et al. Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann Neurol 1993; 34:609–616.PubMedCrossRefGoogle Scholar
  99. 99.
    Lu T, Pan Y, Kao SY et al. Gene regulation and DNA damage in the ageing human brain. Nature 2004; 429:883–891.PubMedCrossRefGoogle Scholar
  100. 100.
    Richter C, Park JW, Ames BN. Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc Natl Acad Sci USA 1988; 85:6465–6467.PubMedCrossRefGoogle Scholar
  101. 101.
    Kanaar R, Hoeijmakers JH. Recombination and joining: Different means to the same ends. Genes Funct 1997; 1:165–174.PubMedGoogle Scholar
  102. 102.
    Karanjawala ZE, Lieber MR. DNA damage and aging. Mech Ageing Dev 2004; 125:405–416.PubMedCrossRefGoogle Scholar
  103. 103.
    Itahana K, Dimri G, Campisi J. Regulation of cellular senescence by p53. Eur J Biochem 2001; 268:2784–2791.PubMedCrossRefGoogle Scholar
  104. 104.
    Lindahl T, Wood RD. Quality control by DNA repair. Science 1999; 286:1897–1905.PubMedCrossRefGoogle Scholar
  105. 105.
    Friedberg EC, Wood RD. DNA exision repair pathways. DNA Replication in Eukaryotic Cells, Cold Spring Harbor Monograph Series 1996;31:249–269.Google Scholar
  106. 106.
    Deng G, Su JH, Ivins KJ et al. Bcl-2 facilitates recovery from DNA damage after oxidative stress. Exp Neurol 1999; 159:309–318.PubMedCrossRefGoogle Scholar
  107. 107.
    Torp R, Su JH, Deng G et al. GADD45 is induced in Alzheimer’s disease, and protects against apoptosis in vitro. Neurobiol Dis 1998; 5:245–252.PubMedCrossRefGoogle Scholar
  108. 108.
    Jacobsen E, Beach T, Shen Y et al. Deficiency of the Mre11 DNA repair complex in Alzheimer’s disease brains. Brain Res Mol Brain Res 2004; 128:1–7.PubMedCrossRefGoogle Scholar
  109. 109.
    Love S, Barber R, Wilcock GK. Increased poly(ADP-ribosyl)ation of nuclear proteins in Alzheimer’s disease. Brain 1999; 122(Pt 2):247–253.PubMedCrossRefGoogle Scholar
  110. 110.
    Kuchino Y, Mori F, Kasai H et al. Misreading of DNA templates containing 8-hydroxydeoxy-guanosine at the modified base and at adjacent residues. Nature 1987; 327:77–79.PubMedCrossRefGoogle Scholar
  111. 111.
    Shigenaga MK, Gimeno CJ, Ames BN. Urinary 8-hydroxy-2′-deoxyguanosine as a biological marker of in vivo oxidative DNA damage. Proc Natl Acad Sci USA 1989; 86:9697–9701.PubMedCrossRefGoogle Scholar
  112. 112.
    Cooke MS, Evans MD, Dove R et al. DNA repair is responsible for the presence of oxidatively damaged DNA lesions in urine. Mutat Res 2005; 574:58–66.PubMedGoogle Scholar
  113. 113.
    Rozalski R, Winkler P, Gackowski D et al. High concentrations of excised oxidative DNA lesions in human cerebrospinal fluid. Clin Chem 2003; 49:1218–1221.PubMedCrossRefGoogle Scholar
  114. 114.
    Hazra TK, Izumi T, Maidt L,et al. The presence of two distinct 8-oxoguanine repair enzymes in human cells: Their potential complementary roles in preventing mutation. Nucleic Acids Res 1998; 26:5116–5122.PubMedCrossRefGoogle Scholar
  115. 115.
    Hermon M, Cairns N, Egly JM et al. Expression of DNA excision-repair-cross-complementing proteins p80 and p89 in brain of patients with Down Syndrome and Alzheimer’s disease. Neurosci Lett 1998; 251:45–48.PubMedCrossRefGoogle Scholar
  116. 116.
    Iida T, Furuta A, Nishioka K et al. Expression of 8-oxoguanine DNA glycosylase is reduced and associated with neurofibrillary tangles in Alzheimer’s disease brain. Acta Neuropathol (Berl) 2002; 103:20–25.CrossRefGoogle Scholar
  117. 117.
    Iida T, Furuta A, Nakabeppu Y et al. Defense mechanism to oxidative DNA damage in glial cells. Neuropathology 2004; 24:125–130.PubMedCrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2007

Authors and Affiliations

  • V. Prakash Reddy
    • 2
  • Ayse Beyaz
    • 2
  • George Perry
    • 1
  • Marcus S. Cooke
  • Lawrence M. Sayre
    • 3
  • Mark A. Smith
    • 1
  1. 1.Institute of PathologyCase Western Reserve UniversityClevelandUSA
  2. 2.Department of ChemistryUniversity of Missouri-RollaRollaUSA
  3. 3.Department of ChemistryCase Western Reserve UniversityClevelandUSA

Personalised recommendations